Liverpool HEP Interactions

Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

No Interaction Expected

Sofosbuvir/Velpatasvir

Levonorgestrel/ethinylestradiol (doses above 20 μg) (COC)

Summary:

Coadministration of a levonorgestrel-containing combined oral contraceptive (COC) has not been studied. Based on drug interaction studies conducted with sofosbuvir alone and velpatasvir alone, no clinically significant drug interactions have been observed with an oral contraceptive containing ethinylestradiol and another progestogen, norgestimate. Coadministration of a once daily triphasic oral contraceptive containing ethinylestradiol (0.025 mg) and norgestimate (0.180/0.215/0.25 mg) with sofosbuvir (400 mg once daily) or velpatasvir (100 mg once daily) was studied. When administered with sofosbuvir, ethinylestradiol Cmax and AUC increased by 15% and 9%, but Cmin decreased by 1% (n=15). When administered with velpatasvir, ethinylestradiol Cmax and AUC increased by 39% and 4%, but Cmin decreased by 17% (n=12). No dose adjustment of oral contraceptives is required.

Description:

No dose adjustment of oral contraceptives is required. Coadministration of norgestimate/ ethinyl estradiol (norgestimate 0.180 mg/ 0.215 mg/ 0.25 mg/ ethinyl estradiol 0.025 mg) and sofosbuvir (400 mg once daily) had no effect on ethinyl estradiol Cmax, AUC or Cmin. There was no change in norelgestromin Cmax, AUC or Cmin; norgestrel Cmax was unaltered, but AUC and Cmin both increased by 20%. Coadministration of norgestimate/ ethinyl estradiol (norgestimate 0.180 mg/ 0.215 mg/ 0.25 mg/ ethinyl estradiol 0.025 mg) and velpatasvir (100 mg once daily) increased ethinyl estradiol Cmax by 40%, had no effect on AUC, and decreased Cmin by 17%. There was no change in the Cmax, AUC or Cmin of norelgestromin or norgestrel.

Epclusa Summary of Product Characteristics, Gilead Sciences Ltd., March 2021.

Based on drug interaction studies conducted with sofosbuvir and velpatasvir, no clinically significant drug interactions have been observed with ethinyl estradiol/norgestimate. Coadministration of a once daily triphasic oral contraceptive containing ethinyl estradiol (0.025 mg) and norgestimate (0.180/0.215/0.25 mg) with sofosbuvir (400 mg once daily) or velpatasvir (100 mg once daily) was studied. When administered with velpatasvir, ethinyl estradiol Cmax and AUC increased by 39% and 4%, but Cmin decreased by 17% (n=12); Cmax, AUC and Cmin of norelgestromin decreased by 3%, 10% and 8% and those of norgestrel decreased by 4%, 9% and 8%, respectively (n=13). When administered with sofosbuvir, ethinyl estradiol Cmax and AUC increased by 15% and 9%, but Cmin decreased by 1% (n=15); Cmax, AUC and Cmin of norelgestromin increased by 7%, 6% and 7% and those of norgestrel increased by 18%, 19% and 23%, respectively (n=15).

Epclusa Prescribing Information, Gilead Science Inc., June 2021.

View all available interactions with Sofosbuvir/Velpatasvir by clicking here.

SUPPORTERS

EDITORIAL SUPPORTERS

Awards and commendations